RNAC Stock Analysis: Buy, Sell, or Hold?
RNAC - Cartesian Therapeutics, Inc. Common Stock
$8.65
0.49 (6.00%)
▲
5d:
+39.07%
30d:
+39.97%
90d:
+33.28%
WAIT
LOW Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 14, 2026
4d
Get Alerted When RNAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: RNAC is 16.7% above its trading range ($7.41). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: RNAC is 16.7% above its trading range ($7.41). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: RNAC is currently trading at $8.65, which is considered extended relative to its 30-day fair value range of $6.02 to $7.41.
Technical Outlook: Technically, RNAC is in a downtrend. The price is approaching resistance at $8.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: RNAC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.57 (+311.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAC is in a downtrend. The price is approaching resistance at $8.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: RNAC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.57 (+311.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.02 -
$7.41
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+16.7% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.0%)
- BULLISH: Trading 311.2% below Wall St target ($35.57)
- WARNING: Recommendation downgraded due to 16.7% overvaluation
Trading Range Analysis
30-Day Trading Range
$6.02 -
$7.41
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.95
Resistance Level
$8.69
Current Trend
Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.06
Wall Street Target
$35.57
(+311.2%)
Revenue Growth (YoY)
-92.9%
Earnings Growth (YoY)
-7.4%
Share & Embed Analysis
Last updated: May 09, 2026 12:00 PM ET
Data refreshes hourly during market hours. Next update: 1:00 PM
Data refreshes hourly during market hours. Next update: 1:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Blaine Davis
SELL
10591 shares
2026-01-06
Milos Miljkovic
SELL
3573 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 60 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 63 BUY |
